UBS Starts McKesson (MCK) at Neutral

UBS initiates coverage on McKesson (NYSE: MCK) with a Neutral rating and a price target of $182.00.

Analyst Michael Cherny commented, "We are initiating coverage on McKesson with a Neutral rating and a $182 price target. McKesson has been one of the steadiest performers across healthcare for the last decade, with strong growth in core distribution (pharma and medical) and consistent expansion through M&A. MCK is also generating strategic value for the Technology Solutions business, a long-term underperformer. While headwinds such as branded drug pricing and client losses will slow growth in the short-term, the overhang and uncertainty surrounding drug pricing ahead of the election leaves limited upside for multiple expansion back to normalized levels, thereby capping upside potential."

For an analyst ratings summary and ratings history on McKesson click here. For more ratings news on McKesson click here.

Shares of McKesson closed at $165.67 yesterday.

You May Also Be Interested In

• Lake Street Capital Markets Starts Research Solutions Inc. (RSSS) at Buy
• Nomura/Instinet Downgrades Gujarat State Petronet (GUJS:IN) to Reduce
• JPMorgan Upgrades Samsung SDS Co Ltd (018260:KS) to Overweight